Key facts: SI-BONE Posts 14.5% Revenue Growth; Procedure Volume Rises 19.5%; Analysts Adjust Targets

What happened

SI-BONE reported third-quarter 2026 revenue of $55.7 million, up 14.5% from a year earlier. Procedure volume grew 19.5%, and its net loss narrowed to $3.62 million from $4.57 million. More than 40% of U.S. sacroiliac procedures were performed in ambulatory surgery centers and office-based labs.

Confirmed

Global impact / market context

Revenue and procedure growth indicate that more patients are receiving SI-BONE’s procedures, while the smaller net loss shows improved results but not a return to profit. Greater use of outpatient centers could support procedure growth, though the article gives no detail on its effect on costs or cash available.

Analyst inference

Analysts kept Buy ratings, but their target changes were mixed: UBS and TD Cowen raised targets, while Needham lowered its target. Such targets express analysts’ views, not guaranteed outcomes; revenue growth and a narrowing loss offer investors operating signals, but do not establish future profitability.

Analyst inference

What to watch

1. Check later reports for revenue, procedure volume and net-loss trends; continued growth alongside a narrower loss would show whether the latest operating improvement is sustained. Analyst inference
2. Watch whether the share of U.S. procedures performed in ambulatory surgery centers and office-based labs changes, since the article reports it exceeded 40%. Analyst inference
3. Compare future analyst target changes with SI-BONE’s reported results, while remembering that UBS, TD Cowen and Needham currently retain Buy ratings. Confirmed

Evidence

• Original source link unavailable